Ann: Response to ASX Appendix 4C Query, page-42

Hi Barra, in regards to funds for TAVR, ref second last para.

With any R&D, for either Vaccines or TAVR, the further along the R&D is the more valuable the IP will be, doubt if many majors would sign up for the original concept without that concept being ‘blooded’, as TAVR has been so far.

I would make this call; if it had been the TAVR that had entered the picture years ago, NOT the Vaccines then this company would have been, arguably, in a better place.


There is is far better probability that TAVR potential, imo, would be a better ‘bet’ than the Vaccines R&D.

Fact is this; imo, TAVR will not proceed without a partner, Admedus have no hope of funding this by itself, they done their dash with the expenditure of 10 s of mills thru CRs for the Vacc R&D, 1 mill for their trouble so far, with resulting market sentiment.

TAVR deal can in no way resemble the Vacc deal, there is still no concrete deal, (Vaccines) yet on that even (?), it took far too long.

Are there rival bidders for this or not? if not then it would be a shame, rival bidders on anything normally ensure a better deal.


Single bidder would cover R&D costs at the minimum, minimal upfront?, ..... may mean minimal impact on the sp.

Current situation definitely, imo, favorable for both SB and SIO in the long term, what will seriously impact retail investors meanwhile is the threat of a further CR if Admedus fortunes do not change in the next six months.


Will WP and BOD guarantee there will not be a CR this year!